Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kenporen Expects Record-High Deficit of ¥523.5 Bil. in FY2009
October 4, 2010
- Osteogenesis Promoter Forteo: Eli Lilly
October 4, 2010
- GLP-1 Agonist Liraglutide More Effective Than Sitagliptin:
October 4, 2010
- Sanofi-aventis Starts Multinational PIV ATLAS Study for Lantus
October 4, 2010
- Volibris for Oral Treatment of PAH: GSK
October 4, 2010
- Meta-Analysis Shows Greater Effects of GLP-1 Analogues on HbA1c and Weight
October 4, 2010
- Mylan Opens 24-Hour Customer Support Center
October 4, 2010
- Japan's 5th Biologic for RA Orencia: Bristol Myers
October 4, 2010
- Alogliptin Effectively Reduces HbA1c in Combination with Other Antidiabetic Agents
October 4, 2010
- JAOG Requests Public Funding for HTLV-1 Screening in Pregnancy
October 4, 2010
- Albumin-Bound Paclitaxel Abraxan: Taiho
October 4, 2010
- Lixisenatide Significantly Reduces HbA1c but Not Weight
October 4, 2010
- Meiji HD to Create Meiji Seika Pharma in April 2011
October 4, 2010
- 1,021 HIV-Infected Cases Reported in 2009: Korosho AIDS Survey
October 4, 2010
- Cancer Pain Relieving Agent Tramal: Nippon Shinyaku
October 4, 2010
- BI's SGLT-2 Inhibitor Reduces Both HbA1c and Weight
October 4, 2010
- Kissei Licenses Drug for yperphosphatemia from Vifor Pharma
October 4, 2010
- 19 Products Added to NHI Price List
October 4, 2010
- Dapagliflozin Non-Inferior to SU
October 4, 2010
- Takeda to Construct New Formulation Plant in Hikari
October 4, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…